Drug or treatment

Pirtobrutinib clinical trials

• 33Clinical trials
• 1New in 30 days
• 37Countries

Newest trials

All recruiting trials (33)

• Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP for DLBCL-type Richter Transformation in older or frail adults

  This trial tests a fixed-duration treatment with Pirtobrutinib and Epcoritamab against a mini-CHOP regimen in adults age 80+ or who are frail with Richter transformation.

  Recruiting at 7 sites Phase 2 German CLL Study Group · Melbourne and 11 other locations · NCT07917780

• Pirtobrutinib for Elderly CLL: See if this BTK inhibitor helps older adults

  This study tests whether pirtobrutinib can help people aged 75 and older with chronic lymphocytic leukemia that hasn’t been treated yet.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07685717

• R-PMDT Regimen for Newly Diagnosed PCNSL

  This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07604987

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

• Immune profiling during first-line pirtobrutinib treatment for CLL/SLL

  This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.

  Recruiting Early Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07428707

• Thiotepa with pirtobrutinib and sintilimab for frail or relapsed/refractory CNS lymphoma

  This treatment combines thiotepa with pirtobrutinib and sintilimab for adults who are frail or whose primary or secondary central nervous system lymphoma has relapsed or not responded to prior therapy.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07416890

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor

  This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Newave Pharmaceutical Inc · Skokie, Illinois and 6 other locations · NCT07342478

• Pirtobrutinib plus rituximab for adults with newly diagnosed indolent mantle cell lymphoma

  This trial will test whether combining pirtobrutinib with rituximab is effective and safe for adults newly diagnosed with indolent mantle cell lymphoma.

  Recruiting at 12 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Lisbon, Lisbon District and 15 other locations · NCT07285590

• Pirtobrutinib plus lisaftoclax and rituximab for relapsed or refractory DLBCL

  This trial tests whether combining pirtobrutinib, lisaftoclax, and rituximab helps people with relapsed or refractory diffuse large B‑cell lymphoma who have had at least one prior systemic therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07255963

• Pirtobrutinib combined with venetoclax and rituximab for Waldenström's macroglobulinemia

  This treatment tries combining pirtobrutinib, venetoclax, and rituximab in people newly diagnosed with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma to see if it controls the disease.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT07231952

• Pirtobrutinib added to R-CHOP for newly diagnosed Richter transformation in Lymphoma

  This trial tests whether adding pirtobrutinib to the standard R-CHOP treatment helps people with Richter transformation (a CLL/SLL that becomes aggressive LBCL).

  Recruiting at 62 sites Phase 3 SWOG Cancer Research Network · Irvine, California and 61 other locations · NCT07220187

• Long-term pirtobrutinib treatment for people with previously treated CLL/SLL

  This trial will test whether taking pirtobrutinib long-term is safe for people who have already been treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  Recruiting at 22 sites Phase 4 Eli Lilly and Company · Mobile, Alabama and 49 other locations · NCT07218341

• Comparing a BTK-targeted protein degrader (BGB-16673) with pirtobrutinib for adults with relapsed or refractory CLL or SLL

  This trial tests whether BGB-16673 works better and is as safe as pirtobrutinib for adults whose CLL or SLL has come back or not responded after prior covalent BTK inhibitor treatment.

  Recruiting at 217 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 216 other locations · NCT06973187

• Time-limited combination of pirtobrutinib, venetoclax and obinutuzumab for relapsed CLL/SLL

  This trial will test whether a time-limited combination of pirtobrutinib, venetoclax, and obinutuzumab can control relapsed CLL/SLL in adults who have had prior therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06967610

• Pirtobrutinib plus Mosunetuzumab for relapsed or refractory grade 1–3a follicular lymphoma

  This trial tests whether giving pirtobrutinib together with mosunetuzumab can better treat adults with relapsed or refractory grade 1–3a follicular lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT06948786

• Long-term pirtobrutinib continuation for people with previously treated CLL/SLL or non-Hodgkin lymphoma

  People who are already taking pirtobrutinib in an earlier trial can continue the drug or their follow-up visits so doctors can see if it stays safe and keeps helping over the long term.

  Recruiting at 25 sites Phase 4 Eli Lilly and Company · Miami, Florida and 35 other locations · NCT06876662

• Long-term safety follow-up of pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma

  This program lets people who previously received pirtobrutinib in a Lilly study continue treatment or follow-up so doctors can see if the drug remains safe over the long term.

  Recruiting at 32 sites Phase 4 Eli Lilly and Company · Jacksonville, Florida and 37 other locations · NCT06876649

• Treatment of Chronic Lymphocytic Leukaemia with Pirtobrutinib after Zanubrutinib

  This study is testing if the drug pirtobrutinib can help people with chronic lymphocytic leukaemia who didn’t respond to or relapsed after treatment with zanubrutinib.

  Recruiting Phase 2 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria and 2 other locations · NCT06812715

• Pirtobrutinib for adults with primary immune thrombocytopenia

  This trial tests whether oral pirtobrutinib can help adults with relapsed or treatment‑resistant primary immune thrombocytopenia (ITP) raise platelet counts and reduce bleeding risk.

  Recruiting at 39 sites Phase 1/2 Eli Lilly and Company · Los Angeles, California and 42 other locations · NCT06721013

• Evaluating Pirtobrutinib for patients with relapsed or refractory CLL/SLL

  This study is testing a new medication called Pirtobrutinib to see if it helps people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma feel better after they’ve already tried other treatments.

  Recruiting at 125 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 128 other locations · NCT06588478

• Combination of Pirtobrutinib and Brexucabtagene Autoleucel for Relapsed Mantle Cell Lymphoma

  This study is testing if combining two treatments, Pirtobrutinib and Brexucabtagene Autoleucel, can help people with relapsed mantle cell lymphoma feel better and improve their outcomes.

  Recruiting at 2 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Stanford, California and 2 other locations · NCT06553872

• Combining pirtobrutinib and venetoclax for treating resistant CLL or SLL

  This study is testing if combining two drugs, pirtobrutinib and venetoclax, can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that hasn’t responded to previous treatments.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06466122

• Combining Pirtobrutinib and Rituximab for treating newly diagnosed Marginal Zone Lymphoma

  This study is testing if combining two medications, Pirtobrutinib and Rituximab, can help people who have just been diagnosed with marginal zone lymphoma feel better.

  Recruiting at 2 sites Phase 2 University of Utah · St Louis, Missouri and 1 other locations · NCT06390956

• Fixed-duration treatment for chronic lymphocytic leukemia with pirtobrutinib and obinutuzumab

  This study is testing a year-long treatment combining two medications, pirtobrutinib and obinutuzumab, to see if it helps people with chronic lymphocytic leukemia feel better.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT06333262

• Combination treatment for low and intermediate risk Mantle Cell Lymphoma

  This study is testing a new combination of two drugs, pirtobrutinib and rituximab, to see if it can effectively treat people with low and intermediate risk Mantle Cell Lymphoma without using chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06263491

• Combining glofitamab and pirtobrutinib for treating relapsed or refractory mantle cell lymphoma

  This study is testing if combining two drugs, glofitamab and pirtobrutinib, can help people with relapsed or refractory mantle cell lymphoma feel better and live longer.

  Recruiting at 4 sites Phase 2 University of California, San Francisco · Davis, California and 3 other locations · NCT06252675

• Evaluating Glofitamab Alone or with Other Treatments for Richter's Transformation

  This study is testing if a new treatment called Glofitamab, alone or with other medications, can help people with Richter's Transformation from Chronic Lymphocytic Leukemia feel better.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 4 other locations · NCT06043674

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Combining Glofitamab and Pirtobrutinib for Mantle Cell Lymphoma

  This study is testing if combining two drugs, Glofitamab and Pirtobrutinib, can help people with relapsed or hard-to-treat Mantle Cell Lymphoma feel better and possibly achieve complete remission.

  Recruiting at 2 sites Phase 2 Australasian Leukaemia and Lymphoma Group · Parkville, Victoria and 1 other locations · NCT05833763

• Combination treatment for newly diagnosed chronic lymphocytic leukemia

  This study is testing a new combination treatment for people with newly diagnosed chronic lymphocytic leukemia to see if it helps them achieve better health outcomes.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05536349

• Combining pirtobrutinib and venetoclax for treating relapsed mantle cell lymphoma

  This study is testing if combining two medications, pirtobrutinib and venetoclax, can help people with relapsed mantle cell lymphoma feel better and improve their chances of survival.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05529069

• Pirtobrutinib versus ibrutinib for people with CLL or SLL.

  This trial will test whether pirtobrutinib works better or is safer than ibrutinib for adults with CLL/SLL, with a separate part that tries pirtobrutinib alone in treatment‑naïve patients who have a 17p deletion.

  Recruiting at 93 sites Phase 3 Eli Lilly and Company · Anaheim, California and 142 other locations · NCT05254743

Quick answers

How many clinical trials of Pirtobrutinib are recruiting right now?

33, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 37 countries. The most sites are in United States (25 trials), Australia (9 trials), China (8 trials), France (7 trials), Italy (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 22, Phase 3: 5, Phase 4: 3, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →